Tvardi Therapeutics Inc. TVRD 深 沪
等待开盘 04-03 09:30:00 美东时间
3.02
+0.020
+0.67%
华盛通- 最 高3.04
- 今 开2.90
- 成交量 6.34万股
- 最 低 2.81
- 昨 收 3.00
- 总市值 2833.17万
- 52周最高 43.65
- 市盈率 静 --
- 换手率 0.68%
- 52周最低 2.81
- 委 比 -20.00%
- 总股本 938.13万
- 历史最高 1067.292
- 量 比 0.94
- 振 幅 7.67%
- 历史最低 2.81
- 每 手 1
- 风险率 12.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 绩后爆锤！耐克遭10家大行集体下调目标价；NCNO、RH、艾默生电气等也遭大行下调目标价
今日重点评级关注：Canaccord Genuity：维持Generac控股"买入"评级，目标价从275美元升至300美元；Oppenheimer：维持Biogen"跑赢大市"评级，目标价从250美元升至275美元
04-02 16:17
Piper Sandler Maintains Neutral on Tvardi Therapeutics, Lowers Price Target to $3
Piper Sandler analyst Yasmeen Rahimi maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Neutral and lowers the price target from $4 to $3.
04-02 01:57
Tvardi Therapeutics Q4 EPS $(0.78) Misses $(0.68) Estimate
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.68) by 15.38 percent. This is a 84.21 percent increase over losses of $(4.94) per share
04-01 05:14
Tvardi Therapeutics Provides Updates From Phase 2 REVERT IPF Clinical Trial Of TTI-101 In Idiopathic Pulmonary Fibrosis
Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the placebo groupTopline healthy volunteer data from Phase 1 study of
01-08 21:13
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you ...
2025-11-30 22:46
Tvardi Therapeutics Q3 EPS $(0.59) Beats $(0.92) Estimate
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.92) by 35.8 percent.
2025-11-14 05:32
Tvardi Therapeutics to Present at Jefferies Global Healthcare Conference in London
Tvardi Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies targeting STAT3 for fibrosis-driven diseases, will present at the Jefferies Glo...
2025-11-04 21:02
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
2025-10-14 09:56
Tvardi Therapeutics Said Preliminary Data From Phase 2 REVERT Trial of TTI-101 In Idiopathic Pulmonary Fibrosis Show That The Study Did Not Meet Its Goals
The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI-101 alone or in addition to nintedanib (OFEV®) in patients with IPF. The study was designed to assess
2025-10-13 19:32
Tvardi Therapeutics Announces Preliminary Results from Phase 2 REVERT Trial of TTI-101 in Idiopathic Pulmonary Fibrosis
Tvardi Therapeutics Inc. announced preliminary data from its Phase 2 REVERT clinical trial evaluating TTI-101 in patients with idiopathic pulmonary fibrosis (IPF). The randomized, double-blind, placeb...
2025-10-13 19:30
